Yet, we show that tumor CNA burden retains its prognostic significance after adjustment for a number of known oncogenic alterations in primary prostate cancer, including PTEN loss associated with increased tumor CNA burden (Castro et al., 2015; Williams et al., 2014). The gene discussed is PTEN; the disease is Familial prostate cancer.